ly3871801
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 4, 2022 (NCT05222399)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06049108 | Phase 1 | Sep 15, 2023 | Eli Lilly |
| NCT05960851 | Phase 1 | Aug 9, 2023 | Eli Lilly |
| NCT05848258 | Phase 2 | May 23, 2023 | Eli Lilly, Rigel Pharmaceuticals |
| NCT05602675 | Phase 1 | Nov 2, 2022 | Eli Lilly |
| NCT05222399 | Phase 1 | Feb 4, 2022 | Eli Lilly |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 5 | 5 | 2 | 2022 |
| Rigel Pharmaceuticals | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1